The differing reimbursement positions highlight how health technology assessment decisions can diverge across UK nations, affecting the timing of patient access to new medicines.

EndoSure and Ziwig Endotest will be introduced as complementary diagnostic options, aiming to reduce delays in diagnosis for millions of women affected by endometriosis.